The drug firm Zydus Cadila has recently launched new pressurised metered dose inhaler (pMDI) (Forglyn) for patients with chronic obstructive pulmonary disease (COPD) in India.
The pMDI is a combination of long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA). The administration of the two drugs: formoterol fumarate (LABA) + glycopyrrolate (LAMA) in a single inhalation will improve outcomes due to the desired synergistic effect of the two drugs and better adherence to the treatment.
The company has announced that the Forglyn pMDI will be available at Rs 495 per pack.
COPD is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. It is the third leading cause of death worldwide and in India, an estimated 55.3 million patients suffer from COPD.